Is Kura Oncology, Inc. (KURA) a Buy, Sell, or Hold?
Kura Oncology, Inc.
NASDAQ:KURA
$11.04 USD
-$0.13 (-1.16%)
- Volume
- 1.27M
- Average Volume
- 1.15M
- Market Capitalization
- $858.51M
- P/E Ratio
- -4.86
- Dividend Yield
- 0.00%
- Price Target
- $26.50
- Year High
- $24.17
- Year Low
- $9.18
- Payout Ratio
- $0.00
- Current Ratio
- $11.47
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Select |
| CEO | Dr. Troy Edward Wilson J.D., Ph.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KURA |
| CUSIP | 50127T109 |
| CIK | 0001422143 |
| Web | https://kuraoncology.com |
| Phone | 858 500 8800 |
| Currency | USD |
| Employees | 142 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 11.47 |
| Quick Ratio | 11.47 |
| Cash Ratio | 1.23 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 675.99 |
| Cash Flow | -1.95 |
| Price / Cash Flow | -5.07 |
| Price / Book | 2.27 |
Price Target and Rating
| Average Stock Price Forecast | $26.50 |
| High Stock Price Forecast | $32.00 |
| Low Stock Price Forecast | $11.00 |
| Forecast Upside/Downside | -58.34% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.08 |
| Trailing P/E Ratio | -4.86 |
| PEG Ratio | 0.83 |
| P/E Growth | 0.83 |
| Net Income | $-152.63M |
| Net Margin | -15555.28% |
| Pretax Margin | -15555.28% |
| Return on Equity | -44.09% |
| Return on Assets | -41.26% |
Financials Score
| AltmanZ Score | 6.50 |
| Piotroski Score | 3.00 |
| Working Capital | 422.82M |
| Total Assets | 478.84M |
| Ebit | -195.94M |
| Market Cap | 858.51M |
| Total Liabilities | 55.07M |
Poll Results
About Kura Oncology, Inc. (NASDAQ:KURA) Stock
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in pati ... ents with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
2024-11-25 07:30:00
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
2024-11-20 17:52:28
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
2024-11-20 17:00:00
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the U.S. – – Companies to jointly pursue broad development program targeting acute leukemias, including frontline indications, combinations with targeted therapies and post-transplant maintenance setting – – Kura anticipates collaboration funding along with current cash balance to support AML program advances through commercialization in frontline combination therapy – SAN DIEGO and TOKYO , Nov. 20, 2024 /PRNewswire/ -- Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.
2024-11-20 17:00:00
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
2024-11-09 05:54:58
Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Doyle - Senior Vice President, Finance and Accounting Dr. Mollie Leoni - Executive Vice President, Clinical Development Conference Call Participants Li Watsek - Cantor Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Charles Zhu - LifeSci Capital Phil Nadeau - TD Cowen Peter Lawson - Barclays Justin Zelin - BTIG Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call.
Frequently Asked Questions
-
What is the current Kura Oncology, Inc. (KURA) stock price?
-
Kura Oncology, Inc.(NASDAQ:KURA) stock price is $11.04 in the last trading session. During the trading session, KURA stock reached the peak price of $24.17 while $9.18 was the lowest point it dropped to. The percentage change in KURA stock occurred in the recent session was --1.16% while the dollar amount for the price change in KURA stock was -$-0.13.
-
KURA's industry and sector of operation?
-
The NASDAQ listed KURA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KURA?
-
Mr. Thomas Doyle | Senior Vice President of Finance & Accounting
Dr. Stephen Dale M.D. | Chief Medical Officer
Ms. Maureen Clancy M.B.A. | Vice President and Global Head of Program Leadership & Project Management
Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing & Supply Chain
Dr. Mollie Leoni M.D. | Executive Vice President of Clinical Development -
How many employees does KURA have?
-
Number of KURA employees currently stands at 142. KURA operates from 12730 High Bluff Drive, San Diego, CA 92130, US.
-
Link for KURA official website?
-
Official Website of KURA is: https://kuraoncology.com
-
How do I contact KURA?
-
KURA could be contacted at phone #858 500 8800 and can also be accessed through its website. KURA operates from 12730 High Bluff Drive, San Diego, CA 92130, US.
-
How many shares of KURA are traded daily?
-
The average number of KURA shares traded daily for last 3 months was 1.15M.
-
What is the market cap of KURA currently?
-
The market value of KURA currently stands at $858.51M with its latest stock price at $11.04